Mereo completes enrollment in Phase II of acumapimod for COPD exacerbations

Mereo BioPharma Group plc (LSE:MPH) completed enrollment of 282 patients in the international Phase II AETHER trial evaluating acumapimod (BCT-197) to treat acute exacerbations of chronic obstructive pulmonary disease (COPD). The company expects top-line data in 2H17.

Patients in the double-blind, placebo-controlled trial will receive 1 of 2 doses of oral acumapimod on days 1-5. AETHER’s primary endpoint is change in forced expiratory volume in 1 second (FEV1) at day 7. Patients will also be assessed for hospital stay times, patient-reported outcomes and recurrence rate...